QSAR study on aminophenylbenzamides and acrylamides as histone deacetylase inhibitors: An insight into the structural basis of antiproliferative activity

Medicinal Chemistry Research

Volumn 16, Issue 7-9, 2007, Pages 449-460

  Dessalew, Nigus ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

Aminophenylacrylamides; Aminophenylbenzamides; Drug design; Histone deacetylases; QSAR; Tool for Structure Activity Relationships (TSAR)

Indexed keywords

ACRYLAMIDE; AMINOPHENYLBENZAMIDE; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG BINDING; DRUG STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 51749087688     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-007-9085-9     Document Type: Article

References (31)

1. KV Anderson JA Lengyel 1980 Changing rates of histone mRNA synthesis and turnover in Drosophila embryos Cell 21 717 727
2. G Bouchain S Frechette SH Woo EA Khalil S Leit M Fournel PT Yan MC Trachy-Bourget C Beaulieu Z Li J Besterman D Delorme 2001 Design and synthesis of a novel class of histone deacetylase inhibitors Bioorg Med Chem Lett 11 2847 2850
3. N Carey BN Thangue 2006 Histone Deacetylase Inhibitors: Gathering Pace Curr opin Pharmacol 6 369 375
4. B Chen PA Petukhov Jung Ml A Valena A Eliseeva A Dritscilo P Kozikowski 2005 Chemistry and biology of mercaptoacetamides as novel histone reacetylase inhibitiors Bioorg Med Chem Lett 15 1389 1392
5. M Curtin K Glaser 2003 Histone deacetylase inhibitors: the Abbott experience Curr Med Chem 10 2373 2392
6. HJ Chang HJ Kim HS Chun 2007 Quantitative structure-activity relationship (QSAR) for neuroprotective activity of terpenoids Life Sci 80 835 841
7. N Dessalew PV Bharatam 2007 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: An insight into the criteria for selectivity Eur J Med Chem 42 1014 1027
8. N Dessalew DS Patel PV Bharatam 2007 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3b inhibitors J Mol Graph Mod 25 885 895
9. N Dessalew PV Bharatam SK Singh 2007 3D-QSAR CoMFA Study on aminothiazole derivatives as cyclin-dependent kinase 2 inhibitors QSAR Comb Sci 26 85 91
10. VA Garea M Esteller 2004 Histone deacetylase inhibitors; understanding a new wave of anticancer agents Int J Cancer 112 171 178
11. B Jose Y Oniki T Kato N Nishino Y Sumida M Yoshida 2004 Novel histone deacetylase inhibitory activity of cyclic tetrapeptide with trifluoromethyl and pentafluoro ethyl ketones Bioorg Med Chem Lett 14 5343 5346
12. J Klocker B Wailzer G Buchbauer P Wolschann 2002 Bayesian neural networks for aroma classification J Chem Inf Comput Sci 42 1443 1449
13. MH Knaggs C McGuigan SA Harris P Heshmati D Cahard IH Gilberta J Balzarini 2000 A QSAR study investigating the effect of L-alanine ester variation on the anti-HIV activity of some phosphoramidate derivatives of d4T Bioorg Med Chem Lett 10 2075 2078
14. A Kovatcheva G Buchbauer A Golbraikh P Wolschann 2003 QSAR Modeling of alpha-campholenic derivatives with sandalwood odor (2003) J Chem Inf Comput Sci 43 259 266
15. H Kubinyi 1997 QSAR and 3D-QSAR in drug design Part 1: methodology Drug Discovery Today 2 457 467
16. BB Lohray N Gandhi KB Srivastava VB Lohray 2006 3D QSAR studies of N-4-arylacryloylpiperazin-1-yl-phenyloxazolidinones: A novel class of antibacterial agentsq Bioorg Med Chem Lett 16 3817 3823
17. CM Marson T Mahadevan J Dines S Sengmany JM Morrell JP Alao SP Joel DM Vigushin RC Coombes 2007 Structure activity relationships of aryloxy alkanoicacid hydroxamides as potent inhibitors of histone deacetylases Bioorg Med Chem Lett 17 136 14
18. F McLaughlin P Finn NB La Thangue 2003 The cell cycle, chromatin and cancer: mechanism based therapeutics come of age Drug Disc Today 8 793 802
19. F McLaughlin NB La Thangue 2004 Histone deacetylase inhibitors open new doors in cancer therapy Biochem Pharmacol 68 1139 1144
20. O Mordei S Leit N Zhou F Frechette C Bouchain HS Woo I Paguin S Raeppel S Frechette A Vaisburg M Fournal A Kalita A Lu M Claude T Bourget P Yan J Liu Z Li J Rahil RA Macleod MJ Besterman D Delorme 2006 Substituted N-(2-aminophenlyl)-benzamides, (E)-N-(2-aminophenyl)-acryl amides and their analogues: Novel classes of histone deacetylase inhibitors Bioorg Med Chem Lett 16 4048 4052
21. C Monneret 2005 Histone deacetylase inhibitors Eur J Med Chem 40 1 13
22. N Nishino D Yoshikawa LA Blatanbe T Kato BL Jose Y Komatsu R Shinta M Yoshida T Kato 2004 Chlamydocin-hydroxamic acid analogues as histone deacetylase inhibitors Bioorg Med Chem Lett 12 5777 5784
23. PP Pandolfi 2001 Transcription therapy for cancer Oncogene 20 3116 3127
24. AG Inche NB La Thangue 2006 Keynote review: Chromatin control and cancer-drug discovery: realizing the promise Drug Discovery Today 11 97 109
25. R Somech S Izraeli JA Simon 2004 histone deacetylase inhibitors- a new tool to treat cancer Cancer Treatm Rev 30 401 472
26. C Shinji T Nakamura S Maeda M Yoshida Y Hashimoto H Miyachi 2005 Design and synthesis of phthalimide-type histone deacetylase inhibitors Bioorg Med Chem Lett 15 4427 4431
27. S Uesato M Kitagawa Y Nagaoka T Maeda H Kuwajima T Yamori 2002 Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group Bioorg Med Chem Lett 12 1347 1349
28. Verloop A, Tipker HW (1976a) Development and application of new steric substituent parameters in drug design. In: Ariens EJ (ed.), Drug design 7, 165-207. New York: Academic
29. A Verloop J Tipker 1976 Use of linear free energy related and other parameters in the study of fungicidal selectivity Pestic Sci 7 379 390
30. Verloop A, Tipker JA (1977) Comparative study of new parameters in drug design. In: Keverling BJA (ed.) Biological activity and chemical structure. Amsterdam: Elsevier pp. 63-81
31. H Weinmann E Ottow 2004 recent advances in medicinal chemistry of histone deacetylase inhibitors Ann Rep Med Chem 39 185 196